Menin-MLL inhibitor MI-2

Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) [1].

Product Specifications

CAS Number

[1271738-62-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MI-2.html

Concentration

10mM

Purity

99.81

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CCCC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1

Molecular Formula

C18H25N5S2

Molecular Weight

375.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology (2012), 8 (3), 277-284.